WallStreetZenWallStreetZen

NYSE: MRK
Merck & Co Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Merck & Co earnings were $17.4B for the trailing 12 months ending Mar 31, 2025, with 657.1% growth year over year. The latest MRK earnings report on Mar 31, 2025 announced Q1 2025 earnings of $5.1B, up 35.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRK reported annual earnings of $17.1B, with 4,589.6% growth. The next MRK earnings date is Jul 29, 2025.

MRK past earnings growth

How has MRK's earnings growth performed historically?

Company
657.14%
Industry
114.49%
Market
33.86%
MRK's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
MRK's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
MRK's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

MRK earnings history

Current Revenue
$63.9B
Current Earnings
$17.4B
Current Profit Margin
27.3%
MRK's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

MRK Return on Equity

Current Company
38.2%
Current Industry
53.5%
Current Market
31.3%
MRK's Return on Equity (38.2%)... subscribe to Premium to read more.
High Return on Equity Performance

MRK undefined

Current Company
15.1%
Current Industry
10.1%
MRK is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MRK announces earnings.

MRK undefined

Current Company
23.83%
Current Industry
17.1%
MRK has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MRK vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MRK$26.05B$17.43B+11.60%$6.89
AZN$17.68B$7.77B+34.22%$2.51
NVS$26.42B$12.86B+3.93%$6.44
AMGN$15.28B$5.93B-2.97%$11.05
PFE$14.27B$7.88B-13.01%$1.39
View Top General Drug Manufacturer Stocks

MRK earnings dates

Next earnings date
Jul 29, 2025

Merck & Co Earnings Reports & History FAQ

What were Merck & Co's earnings last quarter?

On MRK's earnings call on Invalid Date, Merck & Co (NYSE: MRK) reported Q1 2025 earnings per share (EPS) of $2.01, up 6.91% year over year. Total MRK earnings for the quarter were $5.08 billion. In the same quarter last year, Merck & Co's earnings per share (EPS) was $1.88.

If you're new to stock investing, here's how to buy Merck & Co stock.

When does Merck & Co report earnings?

The next MRK earnings call is Invalid Date. Add MRK to your watchlist to be reminded of Merck & Co's next earnings date.

Is Merck & Co profitable or losing money?

As of the last Merck & Co earnings report, Merck & Co is currently profitable. Merck & Co's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $17.43 billion, a 656.03% increase year over year.

What was MRK's earnings growth in the past year?

As of Merck & Co's earnings date in Invalid Date, Merck & Co's earnings has grown 657.14% year over year. This is 542.65 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 114.49%. MRK earnings in the past year totalled $17.43 billion.

What are Merck & Co's earnings expectations?

The current EPS estimate for Merck & Co's earnings report in Invalid Date is $2.06.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.